Susquehanna Fundamental Investments, LLC Bio Line Rx Ltd. Transaction History

Susquehanna Fundamental Investments, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.98 - $3.06 $37,671 - $58,219	-19,026 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$2.63 - $4.88 $146,228 - $271,328	-55,600 Reduced 74.5%	19,026 $53,000
Q1 2021 May 17, 2021	BUY	$2.38 - $4.0 $79,968 - $134,400	33,600 Added 81.9%	74,626 $208,000
Q4 2020 Feb 16, 2021	BUY	$1.47 - $3.62 $60,308 - $148,514	41,026 New	41,026 $103,000

3.35M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $13.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.